HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Protarga Inc.

Division of Daiichi Sankyo Co. Ltd.

Latest From Protarga Inc.

Clavis Pharma AS

Norwegian biotechnology company Clavis Pharma was spun out of Norsk Hydro in August 2001 to commercialize Lipid Vector Technology (LVT). LVT conjugates fatty acids to existing therapeutics to improve their ability to enter target cells. Clavis' first product is an LVT derivative of Ara-C, a common chemotherapy for blood cancers, which the firm is testing in solid tumor indications.

BioPharmaceutical Europe

Sympore GMBH

Sympore aims to develop new, improved versions of both existing medicines as well as novel drugs by elucidating and harnessing the natural mechanisms that underlie directed transport in the body.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Neuromedica Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Daiichi Sankyo Co. Ltd.
  • Senior Management
  • Nigel L Webb, PhD, Pres. & CEO
    Robert Dickey IV, VP, Fin. & Corp. Dev. & CFO
    Forrest Anthony, MD, PhD, VP, Clinical Dev.
  • Contact Info
  • Protarga Inc.
    Phone: (610) 592-4000
    2200 Renaissance Blvd.
    Suite 450
    King of Prussia, PA 19406